Objective:
To evaluate the association of GLP-1 receptor agonist continuation during the first trimester of pregnancy with nonlive birth, abnormal fetal growth, and congenital malformations.
Key Findings:
- Estimated 30% risk of nonlive birth among patients who continued treatment compared to 27% among those who did not; adjusted risk ratio of 1.09 suggests no significant difference in risk.
- No clear increase in fetal growth abnormalities or major congenital malformations was identified; major congenital malformations occurred in about 8% of infants exposed to continued treatment and 7% in the noncontinuation group.
- Elective termination was more frequent among patients who continued treatment.
Interpretation:
The findings suggest no strong association between first-trimester GLP-1 receptor agonist continuation and adverse pregnancy outcomes, though uncertainty remains for less common outcomes.
Limitations:
- Observational design may leave residual confounding, particularly related to glycemic control.
- Most patients classified as continuers received only one additional prescription, limiting assessment of prolonged exposure.
- Study could not evaluate pregnancy losses prior to clinical recognition.
- Estimates for major congenital malformations and small for gestational age were imprecise due to small event numbers.
Conclusion:
The study suggests no strong effect of GLP-1 receptor agonist continuation into the first trimester on adverse pregnancy outcomes, which is important for clinical decision-making.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
